Vagomimetic effects of fingolimod: physiology and clinical implications - Wikidata - wikimedia - TriplyDB

Vagomimetic effects of fingolimod: physiology and clinical implications

Vagomimetic effects of fingolimod: physiology and clinical implications

http://www.wikidata.org/entity/Q27025730

about

Use of Fingolimod in the Management of Relapsing-Remitting Multiple Sclerosis: Experience from Latin America Bitopic Sphingosine 1-Phosphate Receptor 3 (S1P3) Antagonist Rescue from Complete Heart Block: Pharmacological and Genetic Evidence for Direct S1P3 Regulation of Mouse Cardiac Conduction.Impact of Age and Polytherapy on Fingolimod Induced Bradycardia: a Preclinical Study.Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis.Fingolimod (Gilenya® ) in multiple sclerosis: bradycardia, atrioventricular blocks, and mild effect on the QTc interval. Something to do with the L-type calcium channel?Sequence of cardiovascular autonomic alterations after fingolimod initiation.

P2860

Q35907969-70F4C50C-EA32-4614-9536-D58624E61354 Q36432399-663BCBC3-FC92-44D9-B167-880A08CDA389 Q38763068-318B9AC6-25C2-435D-8808-4405C52C0A30 Q42694313-449E016E-38AF-453A-9FBB-6A148EF2FF3B Q46480858-C9BE2D65-8699-4555-A73C-11B1BBF5C721 Q48248422-74E6E693-FEB1-4534-9042-F3DF304E14AD

P2860

Vagomimetic effects of fingolimod: physiology and clinical implications

http://www.wikidata.org/entity/Q27025730

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Vagomimetic effects of fingolimod: physiology and clinical implications

@ast

Vagomimetic effects of fingolimod: physiology and clinical implications

@en

Vagomimetic effects of fingolimod: physiology and clinical implications

@nl

type

label

Vagomimetic effects of fingolimod: physiology and clinical implications

@ast

Vagomimetic effects of fingolimod: physiology and clinical implications

@en

Vagomimetic effects of fingolimod: physiology and clinical implications

@nl

prefLabel

Vagomimetic effects of fingolimod: physiology and clinical implications

@ast

Vagomimetic effects of fingolimod: physiology and clinical implications

@en

Vagomimetic effects of fingolimod: physiology and clinical implications

@nl

P1433

Q27025730-53EA5526-84FA-4234-A344-964F3738BBC4

P1476

Q27025730-2B13CB04-046A-440D-A8A1-86645B508E50

P2093

Q27025730-9280F4D4-D0C9-4430-8CC7-0F4397F53645

Q27025730-D0D630A4-39A5-4359-84EC-BB52CCA60513

Q27025730-FA24E192-9C60-4D87-8361-FFD50FBF7444

P275

Q27025730-494AF771-FE92-4471-8038-D55AAC49FD37

Q27025730-6FDD4969-130E-438B-8423-811DCEB9019E

P2860

Q27025730-0359D647-9513-4D48-B518-542CF50650DB

Q27025730-0F50C1FE-E81F-4768-8732-2C163CD15D01

Q27025730-112438CF-C62C-4E27-8149-04B36D524629

Q27025730-115FB91D-C51F-4BA6-9496-1AF257A552B8

Q27025730-1296C6C2-366A-40E2-B56C-6B807FFB2CCB

Q27025730-177DE53B-397A-4020-A4AD-FCB2FAC34A8C

Q27025730-1F09068A-03F9-41A4-A83C-D531C3F11EFA

Q27025730-2A750C90-BE1E-443A-8546-2F6AC14F81DA

Q27025730-2F6AEC3B-4BD6-4F65-9DE4-62E7C4D8A006

Q27025730-32F43270-FA26-403F-8DA5-029501A73081

P304

Q27025730-D315FD38-8BB8-46E0-8E28-2B1EAFFDB299

P31

Q27025730-16A9FB98-ED69-4241-9050-EBC5DD009C6B

Q27025730-7C6C0D08-DB6A-4DF0-A2F7-4235B8B323DD

P356

Q27025730-4CD648DC-F0E4-41AB-AE9C-E2718E69B9FF

P407

Q27025730-D81D463A-A214-4170-8927-62A61F1435D9

P433

Q27025730-0589B468-63A1-4718-B846-FB0990C9E884

P478

Q27025730-C31B6885-1309-431F-A98F-C331CEAE499F

P5008

Q27025730-AA284AF0-FBFB-484E-AFFD-7BD08411E630

P577

Q27025730-952D638E-746C-44E0-B0C7-641157C447C1

Q27025730-9F2862E1-6264-48F6-BA5E-6FEDC6588DD2

P5875

Q27025730-6195B55D-E4C3-4E58-8B75-BD64190C5A33

P698

Q27025730-B7918432-C4D0-4ABE-96D0-D390C67E6BC2

P921

Q27025730-1AF69C5B-DE99-4D7F-A0C0-4806A6E29650

Q27025730-677D6C1E-9EB4-4B14-920E-4EA6E946A85C

Q27025730-C1134CA8-458F-4A86-AA65-BFE1651BCCB3

Q27025730-D66F7A45-E0A9-4761-97BE-FA3783D9AA43

P932

Q27025730-9813AD5B-9D8C-4E22-9A07-AD0544D1C04C

P356

P1433

CNS Neuroscience & Therapeutics

P1476

Vagomimetic effects of fingolimod: physiology and clinical implications

@en

P2093

Emilio Vanoli

http://www.w3.org/2001/XMLSchema#string

Francesco Pentimalli

http://www.w3.org/2001/XMLSchema#string

Gianluca Botto

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

Creative Commons Attribution-NonCommercial-NoDerivatives

P2860

Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

The evaluation and management of bradycardia.

Use of ambulatory electrocardiographic (Holter) monitoring.

Cardiac sarcoidosis: a comprehensive review

Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association

Treatment of persistent sinus bradycardia with intermittent symptoms: are guidelines clear?

Indications for the use of diagnostic implantable and external ECG loop recorders.

Bradyarrhythmias and conduction blocks.

P304

496-502

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CNS.12283

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262423560

http://www.w3.org/2001/XMLSchema#string

P698

24836740

http://www.w3.org/2001/XMLSchema#string

P921

relapsing-remitting multiple sclerosis

atrioventricular block

P932

4204275

http://www.w3.org/2001/XMLSchema#string